CloudMD Software & Services Inc.

Unaudited Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2023 and 2022

(Expressed in thousands of Canadian Dollars, except number of shares and per share amounts)

CLOUDMD SOFTWARE & SERVICES INC.
Unaudited Condensed Interim Consolidated Statements of Financial Position
(in thousands of Canadian Dollars, except number of shares and per share amounts)
(Unaudited)

	Note	March 31, 2023	December 31, 2022
ASSETS			
Current assets			
Cash and cash equivalents		**$ 18,752**	$ 24,058
Trade and other receivables	5	**17,634**	18,758
Inventory		**679**	979
Prepaid expenses, deposits and other		**4,137**	4,195
		41,202	47,990
Assets held for sale	15	**1,051**	3,794
Total current assets		**42,253**	51,784
Deposits		**113**	113
Property and equipment		**7,154**	7,751
Intangible assets		**82,322**	84,558
Goodwill		**42,780**	42,785
Total assets		**$ 174,622**	$ 186,991
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current liabilities			
Accounts payable, accrued liabilities and other		**$ 19,596**	$ 21,023
Deferred revenue		**3,045**	2,256
Contingent consideration	7	**1,282**	2,177
Contingent liability		**1,200**	1,200
Liability to non-controlling interests	8	**1,292**	-
Current portion of lease liabilities		**1,871**	2,015
Current portion of long-term debt		**2,258**	2,157
		30,544	30,828
Liabilities directly associated with the assets held for sale	15	**2,139**	5,917
Total current liabilities		**32,683**	36,745
Contingent consideration	7	**-**	241
Lease liabilities		**3,973**	4,290
Deferred tax liability		**11,290**	11,609
Liability to non-controlling interests	8	**-**	743
Long-term debt	9	**17,426**	17,690
Total liabilities		**65,372**	71,318
SHAREHOLDERS' EQUITY			
Share capital	11	**307,908**	304,817
Reserves		**13,173**	13,143
Shares under escrow		**596**	596
Contingent shares issuable		**2,110**	4,436
Accumulated other comprehensive gain		**114**	186
Deficit		**(215,677)**	(208,532)
Equity attributable to equity holders of the parent		**108,224**	114,646
Non-controlling interest		**1,026**	1,027
Total shareholders' equity		**109,250**	115,673
Total liabilities and shareholders' equity		**$ 174,622**	$ 186,991

Approved and authorized for issuance by the Board of Directors on May 29, 2023.

"Karen Adams"	***"Gaston Tano"***
Karen Adams, CEO	Gaston Tano, Audit Committee Chair

CLOUDMD SOFTWARE & SERVICES INC.
Unaudited Condensed Interim Consolidated Statements of Net loss and Comprehensive Loss
(in thousands of Canadian Dollars, except number of shares and per share amounts)
(Unaudited)

	Note	Three months ended March 31, 2023	Three months ended March 31,2022*
Continuing operations			
Revenue		**$ 26,139**	$ 31,048
Cost of sales		**16,701**	19,643
Gross profit		**9,438**	11,405
Expenses			
Sales and marketing		**1,480**	2,205
Research and development		**590**	992
General and administrative		**9,175**	10,012
Share-based compensation		**30**	490
Amortization of intangible assets		**2,683**	1,802
Depreciation of property and equipment		**738**	803
Acquisition and divestiture-related, integration and restructuring costs		**950**	2,474
Total expenses		**15,646**	18,778
Operating Loss		**(6,208)**	(7,373)
Other income		**160**	139
Change in fair value of contingent consideration		**-**	2,736
Change in fair value of liability to non-controlling interest		**(549)**	(129)
Share in profits of joint venture		**-**	12
Finance costs		**(661)**	(439)
Net loss before taxes from continuing operations		**(7,258)**	(5,054)
Income tax recovery/(expense)		**255**	(85)
Net loss for the period from continuing operations		**(7,003)**	(5,139)
Discontinuing operations			
Loss after tax for the period from discontinuing operations	15	**(143)**	(509)
Net loss for the period		**(7,146)**	(5,648)
Other comprehensive loss			
Item that may be reclassified to income in subsequent periods			
Exchange differences on translation of foreign operations		**(72)**	(136)
Total comprehensive loss for the period		**$ (7,218)**	$ (5,784)
Net loss attributable to:			
Equity holders of the Company		**$ (7,145)**	$ (5,657)
Non-controlling interest		**(1)**	9
Total comprehensive loss attributable to:			
Equity holders of the Company		**(7,217)**	(5,793)
Non-controlling interest		**(1)**	9
Weighted average number of common shares, basic and diluted		**299,423,030**	278,815,984
Loss per share, basic and diluted		**(0.02)**	(0.02)
Loss per share, basic and diluted from continuing operation		**(0.02)**	(0.02)

* Comparative information has been re-presented due to discontinued operations. See note 15.

CLOUDMD SOFTWARE & SERVICES INC.
Unaudited Condensed Interim Consolidated Statements of Changes in Shareholders' Equity
(in thousands of Canadian Dollars, except number of shares and per share amounts)
(Unaudited)

	Share capital	Reserves	Shares under escrow	Contingent shares issuable	Accumulated other comprehensive gain/ (loss)	Deficit	Non-controlling interest	Total
Balance, December 31, 2021	**$ 241,395**	**$ 11,932**	**$ 596**	**$ 8,510**	**$ (227)**	**$ (52,633)**	**$ 791**	**$ 210,364**
Shares issued/issuable for business combinations	53,176	-	-	-	-	-	-	53,176
Contingent shares issued	2,276	-	-	(2,276)	-	-	-	-
Exercise of stock options	87	(37)	-	-	-	-	-	50
Exercise of warrants	275	(5)	-	-	-	-	-	270
Shares issued for services	15	-	-	(15)	-	-	-	-
Share-based compensation	-	490	-	-	-	-	-	490
Other comprehensive loss	-	-	-	-	(136)	-	-	(136)
Net profit/(loss) for the period	-	-	-	-	-	(5,657)	9	(5,648)
Balance, March 31, 2022	**$ 297,224**	**$ 12,380**	**$ 596**	**$ 6,219**	**$ (363)**	**$ (58,290)**	**$ 800**	**$ 258,566**

	Share capital	Reserves	Shares under escrow	Contingent shares issuable	Accumulated other comprehensive gain/ (loss)	Deficit	Non-controlling interest	Total
Balance, December 31, 2022	**$ 304,817**	**$ 13,143**	**$ 596**	**$ 4,436**	**$186**	**$(208,532)**	**$1,027**	**$ 115,673**
Contingent shares issued	2,326	-	-	(2,326)	-	-	-	-
Contingent consideration settled in shares	765							765
Share-based compensation	-	30	-	-	-	-	-	30
Other comprehensive loss	-	-	-	-	(72)	-	-	(72)
Net loss for the period	-	-	-	-	-	(7,145)	(1)	(7,146)
Balance, March 31, 2023	**$ 307,908**	**$ 13,173**	**$ 596**	**$ 2,110**	**$ 114**	**$(215,677)**	**$1,026**	**$109,250**

The accompanying notes are an integral part of these unaudited condensed interim consolidated unaudited financial statements

(in thousands of Canadian Dollars, except number of shares and per share amounts)

	Note	Three months ended March 31, 2023	March 31,2022
Operating activities			
Net loss for the period		**$ (7,146)**	$ (5,648)
Adjustments for			
Interest expense on lease liabilities		**53**	98
Interest expense on long term debt		**608**	399
Deferred tax (recovery) expense		**(319)**	-
Depreication and Amortization		**3,421**	3,012
Share-based compensation		**30**	490
Change in fair value of contingent consideration		**-**	(2,736)
Change in fair value of liability to non-controlling interest		**549**	129
Other		**(31)**	139
Net change in non-cash working capital	12(b)	**(1,510)**	(4,878)
Net cash (used in) operating activities		**(4,345)**	(8,995)
Investing activities			
Acquisition of businesses, net of cash acquired	4	**-**	12,163
Payment of contingent consideration		**(371)**	-
Payments received from net investment in sublease		**-**	34
Purchase of intangible assets		**(499)**	(328)
Proceeds from disposal of business	15	**1,261**	-
Purchase (proceed from sale) of property and equipment		**(53)**	50
Net cash provided by investing activities		**338**	11,919
Financing activities			
Proceeds from exercise of stock options		**-**	50
Proceeds from exercise of warrants		**-**	270
Payment of long-term debt		**(692)**	(606)
Payment of lease liabilities		**(607)**	(821)
Net cash (used in) financing activities		**(1,299)**	(1,107)
Net (decrease) increase in cash and cash equivalents		**$ (5,306)**	$ 1,817
Cash and cash equivalents, beginning of period		**24,058**	45,082
Cash and cash equivalents, end of period		**$ 18,752**	$ 46,899

Supplemental cash flow information (*Note 12*)

1. CORPORATE INFORMATION

CloudMD Software & Services Inc. (“CloudMD” or “the Company”) is a publicly traded company listed on the TSX Venture Exchange (“TSXV”) under the trading symbol DOC, and is incorporated under the laws of British Columbia, Canada. The Company’s corporate office is 2200 HSBC Building, 885 West Georgia Street, Vancouver, British Columbia, Canada, V6C 3EH. These condensed interim unaudited consolidated financial statements comprise the Company and its subsidiaries.

CloudMD is a healthcare services provider that uses a comprehensive personalized approach to support an individual’s mental, physical, and social issues. CloudMD has a complete health ecosystem that connects all points of the healthcare journey through one centralized platform.

2. SIGNIFICANT ACCOUNTING POLICIES

a) Basis of Preparation

The unaudited condensed interim consolidated interim financial statements (“interim financial statements”) have been prepared in accordance with International Accounting Standard (“IAS”) 34 *Interim Financial Reporting*, as issued by the International Accounting Standards Board (“IASB”) and should be read in conjunction with the Company’s last annual consolidated financial statements as at and for the year ended December 31, 2022. They do not include all the disclosures required for a complete set of financial statements prepared in accordance with IFRS standards. The Company has prepared the interim financial statements on the basis that it will continue to operate as a going concern. The Board of Directors considers that there are no material uncertainties that may cast significant doubt over this assumption. They have formed a judgment that there is a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future, and not less than 12 months from the end of the reporting period.

These interim financial statements were authorized for issue by the Board of Directors on May 29, 2023.

b) Basis of Consolidation

These interim financial statements comprise of the financial statements of the Company and its subsidiaries as at March 31, 2023. All inter-company transactions and balances have been eliminated on consolidation.

These interim financial statements incorporate the assets, liabilities and results of the Company and its subsidiaries for the three months ended March 31, 2023, and 2022. As at March 31, 2023, the Company owned 27 subsidiaries that are wholly-owned or controlled by virtue of a management services agreement, based in Canada and the USA, and one majority-owned subsidiary in the USA. (87.5% owned by the Company).

c) Significant Accounting Policies

These interim financialstatements have been prepared in accordance with the accounting policies adopted in the Company’s most recent annual financial statements for the year ended December 31, 2022 except for the following changes in accounting policies:

d) New standards, interpretations and amendments adopted by the Company

Amendments to IAS 1: Classification of Liabilities as Current or Non-current

In January 2020, the IASB issued amendments to paragraphs 69 to 76 of IAS 1 to specify the requirements for classifying liabilities as current or non-current. The amendments clarify:

• What is meant by a right to defer settlement
• That a right to defer must exist at the end of the reporting period

- That classification is unaffected by the likelihood that an entity will exercise its deferral right
- That only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification

The amendments are effective for annual reporting periods beginning on or after January 1, 2023 and must be applied retrospectively. The Company adopted these amendments on January 1, 2023, which did not have a material impact on the Company's financial statements.

Definition of Accounting Estimates - Amendments to IAS 8

In February 2021, the IASB issued amendments to IAS 8, in which it introduces a definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, they clarify how entities use measurement techniques and inputs to develop accounting estimates.

The amendments are effective for annual reporting periods beginning on or after January 1, 2023 and apply to changes in accounting policies and changes in accounting estimates that occur on or after the start of that period. Earlier application is permitted as long as this fact is disclosed. The Company adopted these amendments on January 1, 2023, which did not have a material impact on the Company's financial statements.

Disclosure of Accounting Policies - Amendments to IAS 1 and IFRS Practice Statement 2

In February 2021, the IASB issued amendments to IAS 1 and IFRS Practice Statement 2 Making Materiality Judgements, in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their 'significant' accounting policies with a requirement to disclose their 'material' accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures.

The amendments to IAS 1 are applicable for annual periods beginning on or after January 1, 2023 with earlier application permitted. The Company adopted these amendments on January 1, 2023, which did not have a material impact on the Company's financial statements.

Deferred Tax related to Assets and Liabilities arising from a Single Transaction - Amendments to IAS 12

In May 2021, the Board issued amendments to IAS 12, which narrow the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences.

The amendments should be applied to transactions that occur on or after the beginning of the earliest comparative period presented. In addition, at the beginning of the earliest comparative period presented, a deferred tax asset (provided that sufficient taxable profit is available) and a deferred tax liability should also be recognized for all deductible and taxable temporary differences associated with leases and decommissioning obligations. The Company adopted these amendments on January 1, 2023, which did not have a material impact on the Company's financial statements.

The Company has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

(in thousands of Canadian Dollars, except number of shares and per share amounts)

3. SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS

The preparation of the interim financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

The same accounting policies and methods of computation are followed in these interim financial statements as compared with the most recent audited annual financial statements, except for the new standards, interpretations and amendments adopted by the Company as as described in note 2.d above.

4. BUSINESS COMBINATIONS

On January 14, 2022, the Company acquired all of the issued and outstanding Common Shares of MindBeacon Holdings Inc. ("MindBeacon"), one of North America's leading providers of digital mental health care. The acquisition received all required approvals and the transaction closed on that date. Under the terms of the agreement, shareholders of MindBeacon received 2.285 common shares of CloudMD for each common share of MindBeacon and $1.22 of cash per share. Total consideration paid was $29,271 in cash and $53,176 in common shares of CloudMD (54,820,958 common shares at fair value of $0.97 per share, which was the closing share price of CloudMD shares on January 14, 2022).

The purchase price for this acquisition is as follows:

Purchase price:	**Final**
Fair value of common shares issued	$ 53,176
Cash consideration	29,271
Total consideration paid	**$ 82,447**
Allocated as follows:	
Cash and cash equivalents	41,434
Trade and other receivables	3,916
Prepaid expenses, deposits and other	2,010
Property and equipment	1,127
Customer Relationship	760
Brand	1,000
Therapist Network	950
Software	16,860
Accounts payable, accrued liabilities and other	(6,051)
Deferred revenue	(677)
Deferred tax liability	(378)
Lease liabilities	(866)
Long-term debt	(1,379)
Total net assets acquired	**$ 58,706**
Goodwill acquired	**$ 23,471**

(in thousands of Canadian Dollars, except number of shares and per share amounts)

5. TRADE AND OTHER RECEIVABLES

The following table shows the details of the Company's trade and other receivables:

As at	March 31, 2023	December 31, 2022
Trade receivables	**$ 16,646**	$ 15,699
Other receivables	**2,505**	4,643
Allowance for expected credit losses	**(1,517)**	(1,584)
Total	**$ 17,634**	$ 18,758

6. EXPENSES BY NATURE FOR CONTINUING OPERATIONS

For the three months ended:	March 31, 2023	March, 2022*
Cost of sales	**$ 16,701**	$ 19,643
Marketing and advertising	**874**	1,027
Office and administration	**2,379**	2,021
Professional fees	**1,875**	3,194
Rent on short-term leases	**310**	396
Wages and employee benefits	**6,757**	9,045
Amortization of intangible assets	**2,683**	1,802
Depreciation of property and equipment	**738**	803
Share-based compensation	**30**	490
Total	**$ 32,347**	$ 38,421

**Comparative information has been re-presented due to discountued operations. See note 15.*

.

7. CONTINGENT CONSIDERATION

The following table shows a reconciliation of the contingent consideration liability:

Balance, December 31, 2022	**$ 2,418**
Payment of contingent consideration	(371)
Contingent consideration settled in shares	(765)
Balance, March 31, 2023	**1,282**
Current portion	1,282
Long-term portion	**$ -**

8. LIABILITY TO NON-CONTROLLING INTERESTS

The following table shows a reconciliation of the liability to non-controlling interests:

Balance, December 31, 2022	**$ 743**
Change in fair value	549
Balance, March 31, 2023	**1,292**
Current portion	1,292
Long-term portion	**$ -**

On March 14, 2023, the non-controlling shareholder has notified the Company their intention to exercise the put option granted under the shareholder's agreement. As such the liability has been re-valued using the expected settlement amount of $1,292 (US $955) to acquire the remaining 12.5% interest held by the non-controlling interest. The settlement was completed on May 19, 2023 for the amount accrued and the liability has been reclassified from long term to current on the balance sheet as at March 31, 2023.

(in thousands of Canadian Dollars, except number of shares and per share amounts)

9. LONG TERM DEBT

	March 31, 2023	December 31, 2022
Bank loans:		
Variable interest rate	**$ 17,073**	$ 17,584
Variable interest rate[1]	**6**	25
Fixed interest rate loan[2]	**96**	102
Interest free loans:		
Federal Economic Development Agency loan	**2,449**	2,076
CEBA Loan[3]	**60**	60
Balance	**$ 19,684**	$ 19,847
Current portion	**2,258**	2,157
Long-term portion	**$ 17,426**	$ 17,690

(1) Loan matures on April 30, 2023 and carried interest at prime+1%
(2) Loan matures on November 1, 2026 and carried a fixed interest at 6.22%
(3) Loan matures on December 31, 2023

Bank

The Company, through its subsidiary Oncidium, has credit facilities of up to $62,000 (the "Facilities") comprised of the following:

(1) Revolver Facility of $3,000;
(2) Term Facility of $49,000; and,
(3) Additional term facility of $10,000 subject to lender approval.

On March 28, 2023, the Company amended its credit agreement. Under the terms of the new agreement, the credit parties were expanded to include CloudMD Holdings Inc., Humanacare Organizational Resources Inc. Medical Confidence Inc., and Re: Function Health Group Inc. In addition, the Company can net up-to $2.5 million of cash or cash equivalents that are deposited in a blocked account with the lender against the outstanding debt amount for purposes of calculating the financial covenants.

The Facilities mature on June 30, 2024. Interest accrues daily on advances at the applicable Canadian Dealer Offered Rate ("CDOR") plus a margin of between 2.0% and 3.5% dependent upon certain financial ratios. The fair value of the long-term debt approximates its carrying value. The interest rate on the loans as at March 31, 2023 was 9.08%.

As at March 31, 2023, the Company was in compliance with all financial covenants. The debt is secured by a first-ranking security interest on all present and after-acquired assets of the Company's above listed entities.

Interest free loan

MindBeacon entered into a contribution agreement with the Federal Economic Development Agency for Southern Ontario for up to $4,000 in interest free loans to support its transition into a digital mental health platform provider, with the objective of growing recurring revenue by offering its platform as a service to customers in global markets. The loan is repayable over a period of five years, beginning January 2024. The government grant was calculated using a discount rate of 11.9% ,which is the expected interest rate on a similar type of loan.

(in thousands of Canadian Dollars, except number of shares and per share amounts)

10. RELATED PARTY TRANSACTIONS

Key management personnel include the Company's Board of Directors, members of the senior executive team, close family members, and enterprises which are under common control or controlled by these individuals. The below transactions are in the normal course of business and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

The following is a summary of remuneration of key management and Board of Directors:

		For the three months ended		
		March 31, 2023		**March 31, 2022**
Cash-based compensation	**$**	**546**	$	1,216
Stock-based compensation		**30**		247
Total	**$**	**576**	$	1,463

During the three months ended March 31, 2023, the Company paid $557 (March 31, 2022 - $881) for services acquired and the cost of facility sharing, and the Company received $81 (March 31, 2022 – $57) for services acquired for projects subcontracted to a company controlled by key management of one the Company's subsidiaries for IT development service. At March 31, 2023, there was an amount payable of $798 (December 31, 2022 - $1,479) and amount receivable of $81 (December 31, 2022 - $386). These services were paid for the development of one of the Company's key operational platforms.

During the three months ended March 31, 2023, the Company paid $45 (March 31, 2022 - $12) to a company which owns 12.5% of one of the Company's subsidiaries. The payments made related to processing support for Revenue Cycle Management offering.

11. SHARE CAPITAL

The following is a summary of the share capital activities:

	Number of common shares	Share capital
Balance, December 31, 2022	**294,048,103**	**$ 304,817**
Contingent shares issued	4,018,567	2,326
Contingent consideration settled in shares	3,478,261	765
Balance, March 31, 2023	**301,544,931**	**$ 307,908**

12. SUPPLEMENTAL CASH FLOW INFORMATION

(a) Cash and cash equivalents

As at:	**March 31, 2023**	December 31, 2022
Cash	**$ 13,469**	$ 15,868
Cash equivalents	**5,283**	8,190
Total	**$ 18,752**	$ 24,058

(in thousands of Canadian Dollars, except number of shares and per share amounts)

(b) Other cash flow information

For the three months ended:	**March 31, 2023**	March 31, 2022
Change in non-cash working capital		
Trade and other receivables	**$ 2,072**	$ (1,472)
Inventory	**777**	707
Prepaid expenses, deposits and other	**76**	(205)
Accounts payable, accrued liabilities and other	**(5,224)**	(4,157)
Deferred revenue	**789**	249
	$ (1,510)	$ (4,878)
Non-cash investing activities		
Contingent consideration settled in shares	**$ 765**	-
Shares issued for acquisition of MindBeacon	**-**	$ 53,176

13. CAPITAL MANAGEMENT

The Company's objectives when managing capital are to safeguard its ability to continue as a going concern and to maximize shareholder value. The Company's capital is comprised of equity and long-term debt, net of cash and cash equivalents. The Company manages the capital structure and adjusts in response to changes in economic conditions and the risk characteristics of the underlying assets.

There were no changes to the Company's approach in its management of capital during the period.

The Company is subject to certain financial covenants in its debt obligations. The Company's strategy is to ensure it remains in compliance with all of its existing covenants so as to ensure continuous access to required debt to fund growth. Management reviews results and forecasts to monitor the Company's compliance for both the near-term and the upcoming four quarters.

14. FINANCIAL INSTRUMENTS

The Company's principal financial assets include cash and cash equivalents, and trade and other receivables. The Company's principal financial liabilities comprise of accounts payable and accrued liabilities, contingent consideration, contingent liability, long-term debt, and liability to noncontrolling interest. The main purpose of these financial liabilities is to finance the Company's operations.

The carrying values of cash and cash equivalents, trade and other receivables, and accounts payable, accrued liabilities, contingent liability and other approximate their fair values due to the immediate or short-term nature of these instruments. The carrying value of long-term debt is initially recognized at fair value and subsequently measured at amortized cost using the effective interest method. There were no transfers between levels of the fair value hierarchy.

The fair value of contingent consideration is considered a Level 3 financial instrument and was determined primarily using Monte-Carlo simulations and other pricing methodologies, dependent on the facts of the respective acquisitions. The fair value determination of the contingent consideration required management to make significant estimates and assumptions related to future cash flows of the acquired businesses, volatility rates and with respect to the selection of the discount rates. These reflect the Company's own judgements about the assumptions market participants would use in pricing the assets and liabilities. The significant unobservable inputs used to measure the contingent consideration using the Monte Carlo model are expected cash flows and the risk adjusted discount rate. For contingent consideration estimated using a probability weighted approach, the significant unobservable inputs are the probability that the milestone will be achieved, the expected cash flows, and the risk adjusted discount rate.

(in thousands of Canadian Dollars, except number of shares and per share amounts)

The Company is exposed to credit risk, liquidity risk and market risk. The Company's senior management oversees the management of these risks.

Credit risk

Credit risk is the risk of loss associated with a counterparty's inability to fulfill its payment obligations. Credit risk arises from cash and cash equivalents, and trade and other receivables. To manage credit risk, cash and cash equivalents are held only with reputable and regulated financial institutions.

The Company provides credit to its customers in the normal course of operations. The Company minimizes its credit risk associated with its trade and other receivables by performing credit evaluations on customers, maintaining regular and ongoing contact with customers, routinely reviewing the status of individual trade and other receivables balances, and following up on overdue amounts. Further, trade receivables are monitored on a periodic basis for assessing any significant risk of non-recoverability of dues and provisions are created accordingly.

The Company's exposure to credit risk is considered to be low, given the size and nature of the various counterparties involved and their history of collections. As at March 31, 2023, the Company had $17,634 (December 31, 2022 – $18,758) of trade and other receivables, net of an allowance for expected credit losses of $1,517 (December 31, 2022 - $1,584).

Liquidity risk

Liquidity risk is the risk that the Company cannot meet a demand for cash or fund its obligations as they become due. The Company's management is responsible for reviewing liquidity resources to ensure funds are readily available to meet its financial obligations as they become due, as well as ensuring adequate funds exist to support business strategies and operational growth. The current assets reflected on the statement of financial position are highly liquid.

The maturity profile of the Company's financial liabilities, based on contractual undiscounted payment at each reporting date is:

As at March 31, 2023

	Less than one year	One to five years	More than five years	Total
Accounts payable, accrued liabilities and other	$ 19,596	$ -	$ -	$ 19,596
Contingent consideration	1,282	-	-	1,282
Liability to non-controlling interest	1,292	-	-	1,292
Lease liability	2,340	4,262	-	6,602
Long-term debt	2,708	17,009	339	20,056
	$ 27,218	**$ 21,271**	**$ 339**	**$ 48,828**

As at December 31, 2022*

	Less than one year	One to five years	More than five years	Total
Accounts payable, accrued liabilities and other	$ 21,023	$ -	$ -	$ 21,023
Contingent consideration	2,177	241	-	2,418
Lease liability	2,340	4,869	-	7,209
Long-term debt	2,614	18,143	577	21,334
	$ 28,154	**$ 23,253**	**$ 577**	**$ 51,984**

** Liability to non-controlling interests is not included because the non-controlling interest has not exercised their put opton (see Note 8).*

Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Company is exposed to interest rate risk and foreign currency risk.

a) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's long-term debt obligations with floating interest rates.

At March 31, 2023, the Company had variable rate borrowing loans amounting to $17,079 (December 31, 2022 – $17,609). With all other variables held constant, a 1% increase in the interest rate would have increased the net loss by approximately $43 (March, 2022 – $56) for the three months ended March 31, 2023. There would be an equal and opposite impact on net loss with a 1% decrease in the interest rate.

b) Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Company's exposure to the risk of changes in foreign exchange rates relates primarily to the Company's operating activities (when revenue or expense is denominated in a foreign currency) and the Company's net investments in foreign subsidiaries. The Company's US operations functional currency is USD, and therefore any fluctuation in USD relative to CAD will result in a change in other comprehensive income for the period.

The Company's exposure to foreign currency risk to profit before tax is based on changes in the fair value of unhedged foreign currency monetary assets and liabilities and as at the balance sheet date is immaterial. The impact on the Company's other comprehensive income based on the change in USD to CAD currency rate of 5% for the quarter ended March 31, 2023 would be $613 (March 31, 2022 -$4).

15. DISCONTIUNED OPERATIONS

In September 2022, management committed to a plan to sell the following legal entities:

- South Surrey Medical Clinic ("SSMC") (within the Clinic Services & Pharmacies segment)
- Healthvue Ventures Limited ("Healthvue") (within the Clinic Services & Pharmacies segment)
- Cloverdale Pharmacy Ltd. ("Cloverdale") (within the Clinic Services & Pharmacies segment)
- Steveston Health Centre Ltd. ("Steveston") (within the Clinic Services & Pharmacies segment)
- RX Infinity Inc., RXI Pharmacy Inc. & RXI Health Solutions (collectively "RXI" and within the Clinic Services & Pharmacies segment)
- Cloud Practice Inc.(within the Digital Health Solutions segment)

The above entities also represent the entirety of the Clinic Services & Pharmacies segment. The Company sold 100% of its shares in SSMC, Healthvue and Cloud Practice Inc. on November 1, 2022. The Company sold 100% of its shares in Steveston and Cloverdale Pharmacies on December 19th, 2022. The comparative profit and loss from the component have been re-presented to show the discontinued operation separately from continuing operation.

During the three months ended March 31, 2023, the Company received $1,261 for the settlement of working capital and certain customary holdbacks as part of the sale agreements.

(in thousands of Canadian Dollars, except number of shares and per share amounts)

The results of the entities held-for-sale and other discontinued operations for the periods are presented below:

For the three months ended:	**March 31, 2023**	**March 31, 2022**
Revenue	**$ 876**	$ 10,330
Expenses	**1,013**	10,801
Operating loss	**$ (137)**	$ (471)
Finance costs	**(6)**	(59)
Other income	**-**	21
Loss before tax from discontinuing operations	**$ (143)**	$ (509)
Tax (expense)/benefit	**-**	-
Loss after tax for the period from discontinuing operations	**$ (143)**	$ (509)
Loss per share from discontinuing operations	**(-)**	$ (-)

As at March 31, 2023, RXI has assets of $1,051 less liabilities of $2,139, detailed as below:

	As at March 31, 2023
Accounts receivable	$ 422
Prepaid expenses	49
Inventory	20
Property and equipment	471
Goodwill and intangible assets	89
Accounts payable and accrued liabilities	(1,731)
Lease liability	(408)
Total	**$ (1,088)**

The net cash flows generated/(incurred) by the disposal groups are, as follows:

For the three months ended:	**March 31, 2023**	**March 31, 2022**
Operating	$ (1,147)	$ (247)
Financing	(26)	(346)
Investing	-	(46)
Net cash inflow/(outflow)	$ (1,173)	$ (639)

16. SEGMENTED INFORMATION

The Company has two operating segments and the Company's chief operating decision-maker is the Chief Executive Officer.

Health and Productivity Solutions ("HPS")

Health and Productivity Solutions (formerly Digital Health Solutions) are offered on a subscription or license to use basis. The solutions are sold to companies, insurers, clinics and pharmacies (including those owned by the Company) who use our technology to create connectivity, and improve the healthcare practitioner, client and user experience while creating efficiencies in administration.

Health and Wellness Services ("HWS")

Health and Wellness Servies (formerly Enterprise Health Solutions) provides organizations with physical and mental health navigation and treatment through employee support services. Revenues within this division is earned through two pricing models:

(in thousands of Canadian Dollars, except number of shares and per share amounts)

- Subscription-based pricing model using a price per member per month with an average contractual term of 3 years; and,
- Per-case billing model at an agreed upon rate for services that are used in disability management, occupational health, and other employer services.

The demand for certain services within the HWS division that employ a per-case billing model is subject to seasonal fluctuations. This is attributable to lower patient and consumer visits and engagement in the summer months and around the holiday season at the end of the year. In addition, in our IDYA4 business, revenues tend to be higher in the fourth quarter of the year in-line with U.S. government budget spend.

A breakdown of revenue for each operating segment for the three months ended March 31, 2023 and 2022 is as follows:

		Three months ended		
		March 31, 2023		**March 31, 2022**
Health and Wellness Services	**$**	**21,124**	$	26,019
Health and Productivity Solutions		**5,015**		5,029
Total revenues	**$**	**26,139**	$	31,048

A geographic breakdown of revenue for each operating segment for the three months ended March 31, 2023 and 2022 is as follows:

Revenue		**March 31, 2023**		**March 31, 2022**
Canada	**$**	**20,294**	$	25,799
United States		**5,845**		5,249
Total	**$**	**26,139**	$	31,048

Total assets and total liabilities for each segment and geographic region is not information that is provided to and reviewed by the CODM.